

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)	
)	
Huesca <i>et al.</i>)	Art Unit: 1611
)	
Application No. 10/579,149)	Examiner: Kortney L. Klinkel
)	
Filing Date: January 19, 2007)	Confirmation: 8922
)	
For: ARYL IMIDAZOLES AND THEIR)	
USE AS ANTI-CANCER AGENTS)	

AMENDMENT AND RESPONSE TO FINAL OFFICE ACTION
ACCOMPANYING A REQUEST FOR CONTINUED EXAMINATION

MAIL STOP RCE
Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

BALLARD SPAHR LLP

Customer No. 23859

Sir:

In response to the Office Action June 8, 2009, please consider the remarks below. In the Office Action, the Examiner set a three-month period in which to reply, *i.e.*, by September 8, 2009. Accordingly, Applicants are submitting herewith a Request for Two-Month Extension of Time, which extends the due date to November 8, 2009. Therefore, these papers are timely.

Also enclosed is a Request for Continued Examination and the fee therefore.

Further, enclosed with this paper is a Supplemental Information Disclosure Statement.

Amendments to the Specification begin on page 2 of this paper.

Amendments to the Claims are shown in the listing of claims, which begins on page 3 of this paper.

Remarks begin on page 39 of this paper.